Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

NCT07007065 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07007065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07007065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Recruiting
Start date
November 5, 2025
Completion date
March 31, 2033
Enrollment
561 (estimated)
Sites
135

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration